Vitamin D and Breast Cancer: Mechanistic Update

• Published in: JBMR plus 2021-12, Vol.5 (12), p.e10582-n/a
• Main Author: Welsh, JoEllen
• Format: Article
• Language: English
• Subjects: Animal models; Apoptosis; Autophagy; Binding sites; Breast cancer; CANCER; Carcinogenesis; Cell culture; Cell cycle; Cell differentiation; CELL/TISSUE SIGNALING—ENDOCRINE PATHWAYS; Clinical outcomes; Dietary supplements; Enzymes; Estrogens; Hypercalcemia; Ligands; Mammary gland; Medical prognosis; Metabolism; Metabolomics; Molecular modelling; NUTRITION; Patients; Phagocytosis; Physiology; Proteins; Proteomics; PTH/VIT D/FGF23; Special Issue; Special Issues; Tumors; Vitamin D; Vitamin D receptors; Vitamin deficiency
• ISSN: 2473-4039; 2473-4039
• DOI: 10.1002/jbm4.10582

ABSTRACT The presence of the vitamin D receptor (VDR) in mammary gland and breast cancer has long been recognized, and multiple preclinical studies have demonstrated that its ligand, 1,25‐dihydroxyvitamin D (1,25D), modulates normal mammary gland development and inhibits growth of breast tumors in animal models. Vitamin D deficiency is common in breast cancer patients, and some evidence suggests that low vitamin D status enhances the risk for disease development or progression. Although many 1,25D‐responsive targets in normal mammary cells and in breast cancers have been identified, validation of specific targets that regulate cell cycle, apoptosis, autophagy, and differentiation, particularly in vivo, has been challenging. Model systems of carcinogenesis have provided evidence that both VDR expression and 1,25D actions change with transformation, but clinical data regarding vitamin D responsiveness of established tumors is limited and inconclusive. Because breast cancer is heterogeneous, the relevant VDR targets and potential sensitivity to vitamin D repletion or supplementation will likely differ between patient populations. Detailed analysis of VDR actions in specific molecular subtypes of the disease will be necessary to clarify the conflicting data. Genomic, proteomic, and metabolomic analyses of in vitro and in vivo model systems are also warranted to comprehensively understand the network of vitamin D–regulated pathways in the context of breast cancer heterogeneity. This review provides an update on recent studies spanning the spectrum of mechanistic (cell/molecular), preclinical (animal models), and translational work on the role of vitamin D in breast cancer. © 2021 The Author. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.